U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H15N5O5
Molecular Weight 297.2673
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NELARABINE

SMILES

COC1=NC(N)=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O

InChI

InChIKey=IXOXBSCIXZEQEQ-UHTZMRCNSA-N
InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1

HIDE SMILES / InChI
Molecular Formula C11H15N5O5
Molecular Weight 297.2673
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Arranon is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. It is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Administration of nelarabine in combination with adenosine deaminase inhibitors, such 195 as pentostatin, is not recommended. The most common (≥20%) adverse reactions were: anemia, thrombocytopenia, neutropenia, nausea, diarrhea, vomiting, constipation, fatigue, pyrexia, cough, and dyspnea

CNS Activity

CNS Penetrant
2588
Curator's Comment: Nelarabine is widely distributed throughout the body and lower levels detected in the CNS

Originator

GlaxoSmithKline
197
Curator's Comment: Nelarabine was transfered from GlaxoSmithKline to Novartis http://www.pharmaceutical-journal.com/news-and-analysis/notice-board/transfer-of-products-from-glaxosmithkline-to-novartis/20068469.article

Approval Year

2005
130
Targets

Targets

Primary TargetPharmacologyConditionPotency
DNA
282
Target ID: CHEMBL2311221
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ARRANON

Approved Use

ARRANON is indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. ARRANON is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. (1)

Launch Date

2005
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf#page=2
1500 mg/m² single, intravenous
dose: 1500 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NELARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.4 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf#page=2
1500 mg/m² single, intravenous
dose: 1500 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NELARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf#page=2
1500 mg/m² single, intravenous
dose: 1500 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NELARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16.5 min
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/10694549
75 mg/kg 2 times / hour multiple, intravenous
dose: 75 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
NELARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2900 mg/m2 3 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 2900 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2900 mg/m2, 3 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
1500 mg/m2 3 times / 3 weeks multiple, intravenous
Recommended
Dose: 1500 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1500 mg/m2, 3 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
Other AEs: Somnolence, Convulsions...
Other AEs:
Somnolence (severe)
Convulsions (severe)
Numbness (severe)
Paresthesia (severe)
Weakness (severe)
Paralysis (severe)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
1200 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1200 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1200 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
DLT: Weakness, Ataxia...
Dose limiting toxicities:
Weakness (2 patients)
Ataxia (2 patients)
Confusion (2 patients)
Coma (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
1800 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1800 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1800 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
DLT: Weakness, Ataxia...
Dose limiting toxicities:
Weakness (3 patients)
Ataxia (3 patients)
Confusion (3 patients)
Coma (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
2250 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 2250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2250 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, child
Health Status: unhealthy
Age Group: child
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Other AEs: Somnolence...
Other AEs:
Somnolence (severe, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
AEs

AEs

AESignificanceDosePopulation
Convulsions severe
1500 mg/m2 3 times / 3 weeks multiple, intravenous
Recommended
Dose: 1500 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1500 mg/m2, 3 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
Numbness severe
1500 mg/m2 3 times / 3 weeks multiple, intravenous
Recommended
Dose: 1500 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1500 mg/m2, 3 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
Paralysis severe
1500 mg/m2 3 times / 3 weeks multiple, intravenous
Recommended
Dose: 1500 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1500 mg/m2, 3 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
Paresthesia severe
1500 mg/m2 3 times / 3 weeks multiple, intravenous
Recommended
Dose: 1500 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1500 mg/m2, 3 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
Somnolence severe
1500 mg/m2 3 times / 3 weeks multiple, intravenous
Recommended
Dose: 1500 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1500 mg/m2, 3 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
Weakness severe
1500 mg/m2 3 times / 3 weeks multiple, intravenous
Recommended
Dose: 1500 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1500 mg/m2, 3 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
Ataxia 2 patients
DLT
1200 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1200 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1200 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Coma 2 patients
DLT
1200 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1200 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1200 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Confusion 2 patients
DLT
1200 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1200 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1200 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Weakness 2 patients
DLT
1200 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1200 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1200 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Ataxia 3 patients
DLT
1800 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1800 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1800 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Coma 3 patients
DLT
1800 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1800 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1800 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Confusion 3 patients
DLT
1800 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1800 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1800 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Weakness 3 patients
DLT
1800 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1800 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1800 mg/m2, 3 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Somnolence severe, 1 patient
2250 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 2250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2250 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
unhealthy, child
Health Status: unhealthy
Age Group: child
Sources:
https://pubmed.ncbi.nlm.nih.gov/15908649
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2A6
879

CYP2B6
926

CYP2C8
1057

CYP2C19
2057

P-gp
1741

CYP
110
CYP
303

P-gp
2052
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no [IC50 >100 uM]
CYP2A6
911
 no [IC50 >100 uM]
CYP2B6
1160
 no [IC50 >100 uM]
CYP2C19
2141
 no [IC50 >100 uM]
CYP2C8
1117
 no [IC50 >100 uM]
CYP2C9
2497
 no [IC50 >100 uM]
CYP2D6
2546
 no [IC50 >100 uM]
CYP
150
 no
P-gp
1932
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
303
 no
P-gp
2052
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:63612
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63612
ChemicalBook
CB01011878
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB01011878
eMolecules
32176516
https://www.emolecules.com/cgi-bin/more?vid=32176516
MolPort
MolPort-006-167-760
https://www.molport.com/shop/molecule-link/MolPort-006-167-760
Selleck Chemicals
Arranon
http://www.selleckchem.com/products/Arranon.html
ZINC
ZINC000003823492
http://zinc15.docking.org/substances/ZINC000003823492
PubMed

PubMed

TitleDatePubMed
Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
2015-08
Nelarabine in the treatment of refractory T-cell malignancies.
2010-12-01
Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.
2010-10-28
Rare tumors research in emerging countries.
2010-09-30
Towards the development of a rapid, portable, surface enhanced Raman spectroscopy based cleaning verification system for the drug nelarabine.
2010-09
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.
2010-08
Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
2010-08
New trends in nucleoside biotechnology.
2010-07
Use of clofarabine for acute childhood leukemia.
2010-06-24
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
2010-06-07
Application of new drugs in chronic lymphocytic leukemia.
2010-05-10
A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
2010-02
Hydronephrosis Resulting from Bilateral Ureteral Stenosis: A Late Complication of Polyoma BK Virus Cystitis?
2010
Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.
2009-12-29
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
2009-12-10
Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
2009-10
Novel therapies for relapsed acute lymphoblastic leukemia.
2009-07
Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature.
2009-07
Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.
2009-06-16
Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.
2009-03-23
Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
2009-02-18
Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
2009-02
[Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
2009-01
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
2008-06
Novel purine nucleoside analogues for hematological malignancies.
2008-06
Gateways to clinical trials.
2008-05
Gateways to clinical trials.
2008-04-05
Treating refractory leukemias in childhood, role of clofarabine.
2008-04
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
2008-04
Phase I trial of nelarabine in indolent leukemias.
2008-03-01
Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy.
2008
Nelarabine.
2008
Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
2007-12
Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies.
2007-12
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
2007-12
Nelarabine activity in acute biphenotypic leukemia.
2007-11
Nelarabine: a novel purine antimetabolite antineoplastic agent.
2007-09
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
2007-06-15
In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.
2007-04
New drugs 07, part I.
2007-02
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
2007-01
The long and winding road of the clinical development of Nelarabine.
2007-01
Treatment of acute lymphoblastic leukaemia : a new era.
2007
Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
2006-12
Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
2006-12
[Glaxo Smith Kline. A large oncology pipeline].
2006-10
The legacy of great science: the work of Nobel Laureate Gertrude Elion lives on.
2006-10
Milestones in oncology: introducing a new section.
2006-10
Nelarabine: a new purine analog in the treatment of hematologic malignancies.
2006-09
Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
2006
Patents

Patents

05424295
2
05492897
1
05539098
2
05747472
1
05821236
1
20010044451
27
JP2010526091A
24
JP2011505386A
3
JP2011527579A
29

Sample Use Guides

In Vivo Use Guide
Adult: 1,500 mg/m² over 2 hours on Days 1, 3, and 5 repeated every 21 days Pediatric: 650 mg/m² over 1 hour daily for 5 consecutive days repeated every 21 days
Route of Administration: Intravenous
In Vitro Use Guide
The in vitro efficacy of nelarabine was assessed in a panel of acute lymphoblastic leukaemia (ALL) cell lines. IC50 values were 0.067-2.15 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:13:47 GMT 2025
Edited
by admin
on Mon Mar 31 18:13:47 GMT 2025
Record UNII
60158CV180
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARRANON
Preferred Name English
NELARABINE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
506U78
Code English
NELARABINE [ORANGE BOOK]
Common Name English
NELARABINE [EMA EPAR]
Common Name English
506U
Code English
ATTRIANCE
Brand Name English
nelarabine [INN]
Common Name English
NELZARABINE
Common Name English
NELARABINE [MART.]
Common Name English
MAY
Code English
9H-PURIN-2-AMINE, 9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-
Systematic Name English
NELARABINE [MI]
Common Name English
NELARABINE [VANDF]
Common Name English
9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-9H-PURIN-2-AMINE
Common Name English
NSC-755985
Code English
Nelarabine [WHO-DD]
Common Name English
NSC-686673
Code English
NSC-759876
Code English
NELARABINE [JAN]
Common Name English
NELARABINE [USAN]
Common Name English
GW-506U78
Code English
2-AMINO-9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-9H-PURINE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 125999
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
WHO-ATC L01BB07
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
EU-Orphan Drug EU/3/05/293
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
NDF-RT N0000175595
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
NCI_THESAURUS C1556
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
EMA ASSESSMENT REPORTS ATTRIANCE (AUTHORIZED: PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA)
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
LIVERTOX NBK548515
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
WHO-VATC QL01BB07
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
NDF-RT N0000000233
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
FDA ORPHAN DRUG 184404
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
Code System Code Type Description
MESH
C104457
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
SMS_ID
100000085469
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
WIKIPEDIA
NELARABINE
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
PUBCHEM
3011155
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
DRUG BANK
DB01280
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
DAILYMED
60158CV180
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
MERCK INDEX
m7797
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY Merck Index
INN
7704
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
FDA UNII
60158CV180
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
CHEBI
63612
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
EVMPD
SUB09188MIG
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
RXCUI
274771
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID6046842
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
IUPHAR
7090
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
NSC
686673
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
CAS
121032-29-9
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
NSC
755985
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201112
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
DRUG CENTRAL
1892
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
NCI_THESAURUS
C1704
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
NSC
759876
Created by admin on Mon Mar 31 18:13:47 GMT 2025 , Edited by admin on Mon Mar 31 18:13:47 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Plasma protein binding is independent on nelarabine concentrations.
BINDING
Structure of NELARABINE
EXCRETED UNCHANGED
URINE
Related Record Type Details
Structure of Allantoin
METABOLITE -> PARENT
Structure of XANTHINE
METABOLITE -> PARENT
MINOR
Structure of Guanine
METABOLITE -> PARENT
Structure of 6-METHOXYGUANINE
METABOLITE -> PARENT
Structure of URIC ACID
METABOLITE -> PARENT
Structure of ARAGUANOSINE
METABOLITE ACTIVE -> PRODRUG
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC SINGLE DOSE ADMINISTRATION

NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966